People · Operator

Roger S. Pomerantz

Named in public records as an officer, director or promoter · active 2017–2018 · Biotechnology

1
Companies
2
Filings
$216.2M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Rubius Therapeutics, Inc.BiotechnologySeries D+$216.2M$4.2B2017
Operator network

Roger S. Pomerantz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Peter Barton Hutt · 14 companies · 1 sharedPeter Barton HuttRobert S Langer · 14 companies · 1 sharedRobert S LangerNoubar B Afeyan · 5 companies · 1 sharedNoubar B AfeyanAndrew B. Oh · 1 companies · 1 sharedAndrew B. OhCatherine B. Sohn · 1 companies · 1 sharedCatherine B. SohnChristopher L. Carpenter · 1 companies · 1 sharedChristopher L. Ca…David Straight Epstein · 1 companies · 1 sharedDavid Straight Ep…Francis B. Cuss · 1 companies · 1 sharedFrancis B. CussHarvey F. Lodish · 1 companies · 1 sharedHarvey F. LodishJoanne Protano · 1 companies · 1 sharedJoanne ProtanoMichael Barton Rosenblatt · 1 companies · 1 sharedMichael Barton Ro…Michael S. Rosenblatt · 1 companies · 1 sharedMichael S. Rosenb…Torben Straight Nissen · 1 companies · 1 sharedTorben Straight N…Rubius Therapeutics, Inc. · $216.2M raisedRubius Therapeutics, …Roger S. PomerantzRP
Roger S. Pomerantz Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Roger S. Pomerantz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Robert S Langer114
Peter Barton Hutt114
Noubar B Afeyan15
Christopher L. Carpenter11
Torben Straight Nissen11
Francis B. Cuss11
Catherine B. Sohn11
Michael S. Rosenblatt11
Joanne Protano11
David Straight Epstein11
Andrew B. Oh11
Harvey F. Lodish11
Michael Barton Rosenblatt11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.